PolyPid Ltd. (PYPD) Form 6-K — May 13, 2026
PolyPid Ltd. has initiated a New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, its lead product candidate for preventing surgical site infections. The submission is under a rolling review, with completion expected imminently. The FDA granted a small business waiver of the PDUFA fee, saving the company approximately $4.3 million.
Key figures
- Eps
- -0.35
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -7728
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 19160
- Cash Position
- 10900
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 19174078
- Net Loss
- 7728
- Trade Payables
- 1535
- Deferred Revenues
- 2548
- Other Liabilities
- 401
- Short Term Deposits
- 2021
- Accumulated Deficit
- -309228
- Pre Launch Inventories
- 1106
- Cash And Cash Equivalents
- 8888
- Additional Paid In Capital
- 318008
- Research And Development Expenses
- 5756
- Current Maturities Of Long Term Debt
- 801
- General And Administrative Expenses
- 1590
- Long Term Operating Lease Liabilities
- 383
- Prepaid Expenses And Other Current Assets
- 351
- Marketing And Business Development Expenses
- 414
- Accrued Expenses And Other Current Liabilities
- 3553
- Current Maturities Of Operating Lease Liabilities
- 1159
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.